You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Claims for Patent: 7,374,757

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,374,757

Title:	Modified chimeric polypeptides with improved pharmacokinetic properties
Abstract:	Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides to decrease or inhibit plasma leakage and/or vascular permeability in a mammal.
Inventor(s):	Papadopoulos; Nicholas J. (Lagrangeville, NY), Davis; Samuel (New York, NY), Yancopoulos; George D. (Yorktown Heights, NY)
Assignee:	Regeneron Pharmaceuticals, Inc. (Tarrytown, NY)
Application Number:	11/016,097
Patent Claims:	1. A fusion protein, consisting of (a) a vascular endothelial growth factor (VEGF) receptor component having immunoglobulin-like (Ig) domains consisting of an Ig domain 2 of a first VEGF receptor human Flt1 and Ig domain 3 of a second VEGF receptor human Flk1; and (b) a multimerizing component, wherein the fusion protein binds VEGF. 2. The fusion protein of claim 1, wherein the first VEGF receptor component is upstream of the second VEGF receptor component. 3. The fusion protein of claim 1, wherein the first VEGF receptor component is downstream of the second VEGF receptor component. 4. The fusion protein of claim 1, wherein the multimerizing component comprises an immunoglobulin domain. 5. The fusion protein of claim 4, wherein the immunoglobulin domain is selected from the group consisting of the Fc domain of IgG, and the heavy chain of IgG. 6. A fusion protein encoded by a nucleic acid sequence selected from: (a) SEQ ID NO:15; and (b) nucleic acid sequences which, as a result of the degeneracy of the genetic code, differ from the nucleic acid sequence of SEQ ID NO:15. 7. A fusion protein consisting of immunoglobulin-like (Ig) domain 2 of a first vascular endothelial growth factor (VEGF) receptor upstream of Ig domain 3 of a second VEGF receptor and a multimerizing component, wherein the fusion protein comprises the amino acid sequence SEQ ID NO:16.

Details for Patent 7,374,757

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	November 18, 2011	7,374,757	2019-06-08
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	August 16, 2018	7,374,757	2019-06-08
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 7,374,757

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration
South Africa	200600157	⤷ Subscribe
South Africa	200110068	⤷ Subscribe
Yugoslavia	86901	⤷ Subscribe
World Intellectual Property Organization (WIPO)	2005000895	⤷ Subscribe
World Intellectual Property Organization (WIPO)	02060489	⤷ Subscribe
World Intellectual Property Organization (WIPO)	0075319	⤷ Subscribe
Uruguay	28396	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.